RS Crum Inc. Invests $47,000 in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

RS Crum Inc. bought a new position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 40,463 shares of the company’s stock, valued at approximately $47,000. RS Crum Inc. owned about 0.15% of Calidi Biotherapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Red Wave Investments LLC raised its holdings in Calidi Biotherapeutics by 74.0% in the 4th quarter. Red Wave Investments LLC now owns 80,828 shares of the company’s stock valued at $93,000 after buying an additional 34,367 shares during the last quarter. CPR Investments Inc. raised its holdings in Calidi Biotherapeutics by 80.4% in the 4th quarter. CPR Investments Inc. now owns 101,000 shares of the company’s stock valued at $116,000 after buying an additional 45,000 shares during the last quarter. Drive Wealth Management LLC bought a new position in Calidi Biotherapeutics in the 4th quarter valued at approximately $104,000. Finally, HighTower Advisors LLC bought a new position in Calidi Biotherapeutics in the 4th quarter valued at approximately $118,000. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Stock Performance

Shares of NYSE CLDI opened at $0.85 on Friday. Calidi Biotherapeutics, Inc. has a 52-week low of $0.58 and a 52-week high of $8.30. The company’s 50 day moving average price is $1.00 and its 200-day moving average price is $1.29.

Calidi Biotherapeutics Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.